Literature DB >> 16518520

Accelerated wound healing: multidisciplinary advances in the care of venous leg ulcers.

Cheryl M Bongiovanni1, Michael D Hughes, Robert W Bomengen.   

Abstract

The etiologies of venous leg ulcers have been well known for millennia, and yet there remains no simple solution to this very common problem. Achieving closure of venous leg ulcers is often a lengthy process that is further complicated by the presence of significant comorbidities. The authors present data on healing venous leg ulcers in a cohort of 231 patients, most of whom had 1 or more complicating factors. Our multidisciplinary and aggressive approach to healing venous leg ulcers is described and has resulted in an average healing time of 29 days, a significantly shorter duration of treatment than the reported average of 6 months.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16518520     DOI: 10.1177/000331970605700202

Source DB:  PubMed          Journal:  Angiology        ISSN: 0003-3197            Impact factor:   3.619


  4 in total

1.  New multifunctional textile biomaterials for the treatment of leg venous insufficiency.

Authors:  M Nichifor; M Constantin; G Mocanu; G Fundueanu; D Branisteanu; M Costuleanu; C D Radu
Journal:  J Mater Sci Mater Med       Date:  2008-12-04       Impact factor: 3.896

2.  Complete healing of chronic wounds of a lower leg with haemoglobin spray and regeneration of an accompanying severe dermatoliposclerosis with intermittent normobaric oxygen inhalation (INBOI): a case report.

Authors:  Wolfgang K R Barnikol; Harald Pötzschke
Journal:  Ger Med Sci       Date:  2011-03-30

3.  Impact of lower extremity venous ulcers due to chronic venous insufficiency on quality of life.

Authors:  Sotirios A Koupidis; Kosmas I Paraskevas; Vassilios Stathopoulos; Dimitri P Mikhailidis
Journal:  Open Cardiovasc Med J       Date:  2008-11-28

4.  Effectiveness of acupuncture, special dressings and simple, low-adherence dressings for healing venous leg ulcers in primary healthcare: study protocol for a cluster-randomized open-labeled trial.

Authors:  Jorge Vas; Manuela Modesto; Camila Mendez; Emilio Perea-Milla; Inmaculada Aguilar; Jesus Manuel Carrasco-Lozano; Vicente Faus; Francisco Martos
Journal:  BMC Complement Altern Med       Date:  2008-06-11       Impact factor: 3.659

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.